Updated on 27 October 2014
For the third quarter of 2014, adjusted EPS grew 32 percent to $1.71, versus $1.30 in the third quarter of 2013. Revenue for the quarter grew 31 percent to $4.17 billion in 2014, versus $3.19 billion in 2013. Organic revenue grew 4 percent, with acquisitions, net of divestitures, increasing revenue by 27 percent and currency translation having a negligible effect. Adjusted operating income for the third quarter of 2014 increased 48 percent compared with the year-ago period, and adjusted operating margin expanded to 21.9 percent, compared with 19.4 percent in the third quarter of 2013.
"We are pleased to extend our long track record of consistently delivering strong adjusted EPS growth. We leveraged our solid top-line results and our culture of operational discipline to achieve excellent performance on the bottom line. I'm also pleased to report that the Life Technologies integration is going very well, and it was another great quarter for innovation across our technology platforms," said Mr Marc N Casper, president and chief executive officer, Thermo Fisher Scientific.
He added, "We launched a number of new products during the quarter to strengthen our leadership position in the key markets we serve. Among the highlights was our new Vanquish UHPLC system and columns, a potential game-changer for customers in applied markets who need to analyze high volumes of samples."